Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 29;219(6):e201904107. doi: 10.1083/jcb.201904107

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Pejskova et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure S5. — AURA activity mediates the effects of KIF14 depletion on primary cilia formation. (A) Histograms show localization of CAP350 (red), Ac-tub (gray), and distribution of IFT88 (green) along the primary cilium (N = 5, "norm." means normalized to CAP350) rescued by AURA inhibition (related to to Fig. 7). (B and C) hTERT RPE-1 cells were 48 h transfected with control or KIF14 siRNA, together with either additional siRNA targeting the individual AURA activator or in combination with small-molecule calmidazolium chloride treatment (4 µM) to inhibit calmodulin (CaM) and 24 h serum starved before fixation. (B) Graph showing percentage of ciliated cells and pinpointing NEDD9 and PIFO as modest rescuers of the ciliogenesis defect caused by KIF14 depletion. (C) Graph showing partial cilia length rescues of defects caused by KIF14 depletion by all used AURA activators. (D) Graph quantifying the percentage of cells with SMO localized to the ciliary axoneme after control or KIF14 siRNA transfection, 24 h serum starvation, and 2 µM SAG treatment to HH pathway activation (related to Fig. 8 E). Asterisks indicate statistical significance determined using Tukey's multiple comparisons test.